Background: Erythropoietin therapy should be accompanied by an adequate iron supply in order to avoid functional iron deficiency (FID) related to enhanced erythropoiesis. Therefore, accurate monitoring of the body's iron homeostasis is needed. This study was conducted to investigate whether transferrin receptor (TfR) expression on reticulocytes can reflect iron status in patients with chronic renal failure (CRF). Methods: TfR expression wantibody binding capacity (ABC)x and the proportion of TfR positive reticulocytes (%TfR
Introduction
Erythropoietin (EPO) is a glycoprotein hormone produced by the kidney. The main functions of EPO are the induction of red blood cell (RBC) precursors and the development of RBCs (1) . Decreased EPO synthesis in chronic renal failure (CRF) leads to inadequate red cell production and renal anemia.
Human recombinant erythropoietin (rHuEPO) substitution therapy is commonly used in the treatment of patients with CRF. Consequently, increased RBC production leads to an increased need for iron. If the iron stores are low wabsolute iron deficiency (ID)x or the mobilization of iron from bone marrow is inadequate wfunctional iron deficiency (FID)x, the response to rHuEPO is impaired. Approximately 80% to 90% of patients on rHuEPO treatment need iron supplementation (2) . The patients treated with intravenous iron supplementation need less rHuEPO to maintain the target hemoglobin (Hb) concentrations compared with those without iron supplementation (3) (4) (5) .
Despite its definite advantages, iron supplementation can also harm the human body by promoting oxidative stress (6) . Hence, the target Hb concentrations for patients with CRF is controversial (7, 8) . Complete correction of anemia does not improve patient survival and may even be associated with an increased risk of congestive heart failure, myocardial infarction or stroke (9) . Therefore, in the treatment of renal anemia, the reliable assessment of iron status is important in order to optimize the rHuEPO and iron supplementation in patients with CRF (10) . Furthermore, it is important to determine whether ID is absolute or functional (11, 12) .
Transferrin receptor (TfR) mediates iron-transferrin complexes from plasma into the cells. In the cell, iron is released and a small fragment of TfR is excreted to circulation. This fragment can be measured in a plasma-soluble form (soluble, sTfR) (13) . TfRs are expressed by all human cells and 80% of the TfRs are localized on the surface of the RBC precursors, and are still present on the surface of reticulocytes (14) . In ID, cells express more TfR on their cell surface to capture more iron. This biological process can be measured as TfR expression on reticulocytes using quantitative flow cytometric (FCM) analysis (15) . This analysis may not be dependent on the erythropoietic mass in the same way as plasma sTfR, Hb, hemoglobin; %HYPOm, the percentage of hypochromic red blood cells; %HYPOr, the percentage of hypochromic reticulocytes. Ret were higher in patients who had FID (ns11) than in patients whose iron status was replete (ns23). The boxes indicate the 25th and 75th percentiles, the horizontal line is the median, and the whiskers show minimum and maximum values.
and therefore the FCM method may be a more accurate measurement in the assessment of iron requirements in patients with accelerated erythropoiesis (15) . The aim of this study was to investigate whether the TfR expression on reticulocytes reflects the changes in iron status of patients with CRF. The TfR expression on reticulocytes was compared with the RBC and reticulocyte indices and Hb values, as well as with the widely used serum iron markers.
Materials and methods
The study was approved by the Local Ethics Committee of the Pohjois-Savo Health Care District. A total of 37 patients (26 males, 11 females) in the dialysis unit at the Kuopio University Hospital were enrolled and written informed consent was obtained from each patient. The patients were 35-83 years of age (median 68 years) and had different diagnoses. In most cases, CRF was caused by diabetes mellitus (type I or II) (ns18), hypertension (ns7), IgAnephropathy (ns4) or polycystic kidney disease (ns3). Samples for blood counts were collected twice (the first sample at baseline, and the second sample after 19 or 21 days, reported as 3 weeks) in June 2006. Only one sample was obtained from three patients, and they were excluded from the study. A 2-week pause in iron supplementation preceded the first sample, but between samples most of the subjects received iron supplementation (25-600 mg/week) and rHuEPO treatment (darbepoietin-a 20-200 mg/week or epoietin beta 2000-30,000 IU/week).
Venous blood samples were collected in EDTA (Vacutainer, Becton Dickinson Vacutainer Systems, Plymouth, UK). Blood count analysis with RBC and reticulocyte indices were performed within 2 h using the Advia 120 Hematology System (Siemens, Health Care Diagnostics, Tarrytown, NY, USA) (16) . Analysis of the quantitative expression of TfR on the reticulocytes by FCM was performed within 6 h after sample collection, as described previously (15) . Briefly, Quantum Simply Cellular ᭨ kit beads (Bangs Laboratories Inc., IN, USA) or blood was stained for 20 min with CD71(TfR)-PE monoclonal antibody (mouse anti-human-CD71-PE, clone M-A712, BDPharmingen, San Diego, CA, USA) in the dark at room temperature. After staining, the beads and the samples were centrifuged and washed with phosphate buffered saline (PBS) (Isoton ᭨ II diluent, Coulter Corporation, Miami, FL, USA) twice. The beads were resus- Table 2 The flow cytometric analyses and iron status measurements at 3 weeks in chronic renal failure patients divided into the Hb change groups.
Variables
Patients whose Hb was changed -7. Ret, the percentage of transferrin receptor positive reticulocytes of all reticulocytes; %Retic, the proportion of reticulocytes; HCT, hematocrit; MCV, mean cell volume of red blood cells; MCVr, mean cell volume of reticulocytes; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; IRF-H, high immature reticulocyte fraction; CHm, cellular hemoglobin in red blood cells; CHr, cellular hemoglobin in reticulocytes; TfR, transferrin receptor; TfR-F index, TfR/Log(ferritin).
pended in PBS and kept in the dark prior to analysis. CD71-PElabeled cells were pipetted into new separate tubes, after which PBS and thiazole orange (TO)-FITC solution (Retic-COUNT reagent, BD Biosciences, San Jose, CA, USA) were added. The cells were incubated for an additional 30 min in the dark at room temperature.
A total of 1000 events from blank beads, 4000 events from standard beads, and 200,000 cells from blood samples were analyzed using the FCM wCoulter Epics XL MCL FCM (Coulter Corporation)x. EXPO32 ADC software wXL 4 Color and Analysis (build 219.1), Coulter Corporationx was used for data acquisition and analysis. Peripheral cells and TO positive reticulocytes were gated (15) . The CD71-PE median channel values of the TO positive reticulocytes were compared with the calibration curve based on QSC beads to calculate the antibody binding capacity (ABC) values of cell samples using QuickCal software (version 2.3, Bangs Laboratories Inc.). The proportion of TfR positive reticulocytes in all reticulocytes (%TfR q Ret) was also calculated. After FCM analyses, the EDTA samples were centrifuged and plasma was separated and stored frozen at -208C. Plasma sTfR was measured using an automated immunoturbidometric IDeA TfR-IT assay (Orion Diagnostica, Espoo, Finland), with a Konelab 60i instrument (Labsystems Ltd., Espoo, Finland). Plasma ferritin was measured using a chemiluminescent immunometric assay wDiagnostic Products Corporation (DPC), Los Angeles, CA, USAx with an automated Immulite2000-analyzer (IEMA) (DPC). The TfR-F index was defined as TfR/Log(ferritin).
The changes between the ''3 weeks'' and ''baseline'' samples were calculated. Anemia was defined as Hb -110 g/L (17), and low ferritin was defined as -100 mg/L, in accordance with the clinical routine at the hospital's dialysis unit. The FID group was defined as having a percentage of hypochromic RBCs (%HYPOm) G3.4%, or the percentage of hypochromic reticulocytes (%HYPOr) G43.5% and ferritin )100 mg/L. The ID group was defined as having a ferritin concentration -100 mg/L (15, 18 
Results
At baseline, seven (20%) patients, and at 3 weeks, seven (20%) patients were anemic (Hb-110 g/L). In 24 (71%) patients, Hb changed -7.6% wreference change limit for Hb (19) x (stable), whereas in three (9%) patients Hb increased. In seven (21%) patients, Hb concentrations decreased more than 7.6%. At baseline, 11 (32%) patients had FID, while Ret at baseline and at 3 weeks in patients (ns27) whose Hb concentration remained stable (Hb change -7.5%) or increased, and in patients (ns7) whose Hb concentration decreased (Hb change )7.6%). The boxes indicate the 25th and 75th percentiles, the horizontal line is the median, and the whiskers show minimum and maximum values.
ID and IDqFID were found in one patient each, and 21 (62%) patients had ''replete iron status'', and at 3 weeks, 11 (32%) had FID and 23 (68%) had ''replete iron status'' ( (Figure 1) . However, no difference in TfR ABC and %TfR q Ret was found at baseline between the FID and replete iron status groups. During follow-up, patients whose Hb concentrations had decreased were treated without iron supplementation (ns1) or with iron (25-600 mg/week) (ns6), and without rHuEPO (ns2) or with rHuEPO (ns5) (30-60 mg/week darbepoietin-a or 12,000-24,000 IU/week epoietin-b). Patients whose Hb concentrations were stable or had increased, received no iron (ns1) or 25-500 mg/week iron The TfR ABC on reticulocytes increased during the 3-week follow-up, despite changes in patients' Hb concentrations (baseline 1630, 1009-4063 vs. at 3 weeks 2192, 950-4702, ps0.001). TfR ABC was significantly lower at baseline than at 3 weeks in patients whose Hb was stable or increased compared with patients whose Hb decreased (Table 2, Figure 2 ). The %TfR q Ret was consistently significantly lower at baseline than at 3 weeks in the patients whose Hb decreased, but not in patients whose Hb was stable or increased ( Figure 2) . The FCM analyses, cellular indices and plasma iron status measurements did not differ between patients with stable or increased Hb and patients with decreased Hb at the end of follow-up at 3 weeks (Table 2) . However, the mean increase (3 weeks -baseline) TfR ABC was four-fold higher, and %TfR The changes in TfR expression correlated significantly with the changes in reticulocyte indices wcellular Hb in reticulocytes (CHr), %HYPOrx, cellular Hb in RBCs (CHm) and ferritin (Table 3) . Spearman correlations between %TfR q Ret or TfR ABC and %HYPOr at baseline were 0.530 (ps0.001) and 0.482 (ps0.004), and at 3 weeks 0.518 (ps0.002) and 0.375 (ps0.029), respectively.
When baseline results were divided into two groups according to the %HYPOm (-and G3.4%, ns25 and ns9, respectively), no significant differences were found in TfR ABC on reticulocytes or in %TfR q Ret values between the patients whose %HYPOm was increased and the patients with normal %HYPOm. But when the results were divided into two groups according to the %HYPOr (-and G43.5%, ns24 and ns10, respectively) values, TfR ABC (1567, 1009-4063 vs. 2052, 1339-2617, ps0.049) and %TfR q Ret (27.4, 12.9%-52.4% vs. 35.1, 24.3%-42.4%, ps0.047) were significantly higher in patients with increased %HYPOr. After 3 weeks treatment, there was a significant difference in %TfR q Ret and in TfR ABC between the %HYPOm groups (%HYPOm -3.4%, ns26 or G3.4%, ns8) (Figure 3 ). In the %HYPOr groups (%HYPOr -43.5%, ns23 or G43.5%, ns11) there were statistically significant differences in both %TfR q Ret and TfR ABC concentrations at 3 weeks (Figure 3 ).
Discussion
Reliable assessment of iron status is essential in the treatment of patients with CRF receiving rHuEPO therapy. In this pilot study, a new FCM analysis based on the measurement of TfR expression on reticulocytes was used in a group of patients with CRF. Although the patient population was small and heterogeneous, we found that TfR ABC on reticulocytes and %TfR q Ret increased less in patients whose Hb concentration remained stable or increased, compared with patients whose Hb concentration decreased. Therefore, the results of this study suggests that regardless of iron and rHuEPO treatment, a reduction in Hb leads to an increased need for iron. This is because developing RBCs compensate for the relative ID by increasing TfRs on their cell surface.
TfR expression on reticulocytes correlated well with reticulocyte indices, which may be associated with iron status, since erythroid precursors ensure iron intake by increasing TfR expression on their cell surface. In line with a previous study, FID patients had higher TfR expression on reticulocytes compared with replete iron status patients, even though the percentage of reticulocytes did not differ between these groups (15) . We also found that increased TfR expression correlated with a reduction in ferritin concentrations, implying that TfR expression depends on iron status. An increase in TfR expression was observed irrespective of the changes in Hb concentrations, which could be explained by a response to iron therapy facilitating the maturation of reticulocytes. This is also consistent with the connection between TfR expression and a high immature fraction of reticulocytes, which could be explained by the fact that the more immature the reticulocytes, the more they express TfR on their cell surfaces (14, (20) (21) (22) . Thus, TfR expression may reflect iron homeostasis in the body, and it is also dependent on maturation of the reticulocytes (15, 20) .
Patients with CRF are often treated with rHuEPO which accelerates erythropoiesis, leading frequently to FID if iron substitution is not balanced with erythropoiesis. Hence, monitoring of iron status is necessary in order to identify patients who would benefit from iron supplementation. Laboratory methods for evaluating iron status are often insensitive to FID, which hampers the evaluation of iron needs in patients treated with rHuEPO. Conventionally, iron status has been evaluated using mean cell volume (MCV), mean cell Hb (MCH) and mean cell Hb concentration (MCHC), as well as with serum/plasma proteins (transferrin, transferrin saturation, sTfR, ferritin) (23, 24) . Currently, the more accurate erythroid cell indices reflecting the features of RBCs and reticulocytes w%HYPOm, %HYPOr, CHr, reticulocyte Hb equivalent (RET-He) and RBC Hb equivalent (RBC-He), for examplex are also available (16, 25, 26) . Although these indices are promising methods for screening of iron status, no suitable cut-off thresholds for patients with CRF have been established (5, 12, 27 ).
Transferrin saturation is commonly used in the assessment of iron status, although serum iron concentrations influence the analysis. The concentration of iron in serum fluctuates, depending on diurnal variation, nutritional status, intravenous iron supplementations and rHuEPO treatment (28) . Measurement of serum/plasma sTfR is inaccurate in patients treated with rHuEPO, since high concentrations of sTfR can be caused not only by ID, but also simply by accelerated (e.g., EPO induced) RBC production (18, 29) . Ferritin is an acute phase protein and consequently is increased during infection or in inflammatory conditions (23) . Ferritin concentrations are often high in patients on dialysis due to excessive iron supplementation. However, in addition, CRF itself is an inflammatory state and thereby increases ferritin concentrations. In this study, ferritin concentrations were generally high and none of the patients had ID at 3 weeks. Additionally, baseline ferritin or EPO concentrations did not predict the changes in Hb level after 3 weeks of treatment.
The limitations of this study include the somewhat small and heterogeneous patient population with variable iron supplementations and rHuEPO doses. Despite this, this study supports the notion that TfR ABC on reticulocytes and %TfR q Ret reflect the changes in Hb concentrations and the demand for iron at the cellular level (15) . Therefore, this new FCM method may have potential in assessing iron availability in patients treated with rHuEPO. Further studies are needed to validate this new FCM method in diagnosing iron deficient anemia in dialyzed patients.
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